This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $219,024 Project Grant (R21CA282561) to the University of Texas Health Science Center at Tyler (UTHSCT) to investigate the ability of the CSP7 peptide to inhibit radiation-induced lung injury (RILI) and prevent the development of pulmonary fibrosis in mice. The research aims to develop a novel therapeutic intervention for cancer patients undergoing thoracic radiation therapy, which can...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $260,586 to the University of Wisconsin-Madison to develop a novel positron emission tomography (PET) probe optimized for non-invasive monitoring of disease activity and treatment response in idiopathic pulmonary fibrosis (IPF). The goal is to leverage the team's expertise in matrix biology, small animal imaging, and probe development to optimize a...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Cooperative Agreement award of $570,849, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is funding the development of predictive biomarker panels for late radiation-induced lung and kidney injuries, referred to as the "DEARE-WATCH Project". The goal is to expand existing biomarker panels and develop prototype "LungWatch" and "KidneyWatch" devices to enable early detection and risk assessment of...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to characterize synaptic density changes in the brain using a novel PET biomarker after radiation therapy in rodent models. The $1,474,236 award, effective September 3, 2024 through August 31, 2028, will support the development of a non-invasive method to monitor radiation-induced cognitive decline. Key objectives include: Establishing quantitative PET techniques to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $583,381 to the Research Institute at Nationwide Children's Hospital (RINCH) to develop a non-invasive imaging strategy for quantifying chemotherapy-induced vascular toxicity. The long-term goal is to better understand the role of venous inflammation in predicting the risk of venous thromboembolism (VTE) in pediatric,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $786,139 to The Trustees of the University of Pennsylvania to develop a technique for dynamically imaging lung function in free-breathing subjects using hyperpolarized 129Xe MRI. The goal is to enable a more physiologically relevant assessment of lung function, especially in patient populations with poor breath-hold tolerance. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500.00 to Brigham & Women's Hospital Inc. from February 1, 2025 to January 31, 2027. The project aims to develop and validate a quantitative marker of pulmonary microvascular injury using an AI-based algorithm to assess vascular perfusion from single energy non-contrast CT scans. This marker will be used to investigate the relationship between pulmonary...